Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and
vomiting in patients receiving chemotherapy.
PURPOSE: This phase II trial is studying how well giving aprepitant together with
palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy
in patients receiving chemotherapy for metastatic colorectal cancer.